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In chronic obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), changes in bronchial
microvasculature are present in response to inﬂammatory stimuli. Vascular changes may signiﬁcantly contribute to airway wall
remodelling. Angiogenesis and vascular leakage are prevalent in asthma, while vasodilation and vascular leakage dominate in
COPD. An endothelial dysfunction may be present both in asthma and in COPD. Vascular changes may occur simultaneously
with the thickening of the airway wall and the narrowing of the bronchial lumen. Consequently, pharmacological control of
bronchial vascular remodelling may be crucial for symptom control in asthma and COPD. In asthmatic airways, inhaled steroids
can downregulate vascular remodelling by acting on proangiogenic factors. Additionally, studies on combination therapy with
long-acting β2-agonists and inhaled steroids have provided evidence of a possible synergistic action on components of vascular
remodelling in asthma. In COPD, there is less experimental evidence on the eﬀect of inhaled steroids on airway microvascular
changes. Importantly, vascular endothelial growth factor (VEGF), the most speciﬁc growth factor for vascular endothelium, is
crucially involved in the pathophysiology of airway vascular remodelling, both in asthma and COPD. The inhibition of VEGF and
its receptor may be useful in the treatment of the vascular changes in the airway wall.
1.Introduction
In chronic obstructive airway diseases, such as asthma and
chronic obstructive pulmonary disease (COPD), changes
in bronchial microvasculature are present in response to
inﬂammatory stimuli [1–4]. Vascular changes may signiﬁ-
cantly contribute to airway wall remodelling in asthma and
COPD [1–4]. Importantly, changes in the microvasculature
may occur simultaneously with the thickening of the airway
wall, thereby causing a narrowing of the bronchial lumen
and a decrease in the airway patency [3, 5]. Consequently,
pharmacological control of bronchial vascular remodelling
may be crucial for symptom control in asthma and COPD.
Among the drugs commonly used to treat chronic obstruc-
tive airway diseases, inhaled steroids are the most eﬀectiveon
the inﬂammatory process in bronchial airways [1, 4].
This overview describes the features of the vascular
component of airway remodelling in asthma and COPD and
its possible functional consequences. Moreover, we focus on
the eﬀects of inhaled steroids on vascular remodelling in
asthma and COPD.
2. VascularRemodelling inAsthma
Airway wall remodelling is a distinctive feature of bronchial
asthma [6]. In asthmatic airways, structural changes occur
in all three layers of the airway wall: the inner wall, the
outerwall,andthesmooth-musclelayer(Figure 1).Basically,
the remodelling consists in the shedding of the epithelium,
the increase in mucous glands, thickening of the reticular
basementmembrane, hypertrophyand hyperplasia of airway
smooth muscle, and in qualitative and quantitative changes
in airway blood vessels [7].
The vascular component of airway remodelling in
asthma is arousing more and more interest in researchers,
because bronchial microvasculature has several functions2 International Journal of Endocrinology
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Figure 1: Schematic representation of bronchial airways wall. In
asthma and COPD changes in bronchial microvasculature, such as
angiogenesis, vasodilatation, and microvascular leakage, are present
in response to inﬂammatory stimuli. Considering conventional
therapy, only corticosteroids can positively act on all aspects of
vascular remodelling.
that are essential for maintaining homeostasis. These func-
tions include provision ofoxygenandnutrients, temperature
regulation, and humidiﬁcation of inspired air, as well as
being the primary portal of the immune response to
inspired organisms and antigens [8]. Although there may
be methodological problems in measuring the vascular area
of the bronchial mucosa [9], however, there is evidence
that structural vascular changes may signiﬁcantly occur in
the mucosa of the asthmatic airways. In bronchial asthma,
airway microvascularity may change by increasing vessel
calibre through vasodilation, angiogenesis, and by inducing
interstitial edema within the airway wall, as a consequence
of microvascular leakage [1–4]. Furthermore, in asthmatic
patients the airway microvascularity changes are associated
with an increase in airway blood ﬂow (Qaw)a n db l u n t e dβ2-
adrenergic vasodilator responsiveness [10], the latter ﬁnding
suggesting the presence of endothelial dysfunction. The role
of endothelial dysfunction in the pathogenesis of bronchial
asthmaisnotyetfullyclariﬁedanditstillremainstoascertain
whether or not it is an epiphenomenon [11].
In asthmatic airways, a link between airway inﬂamma-
tion and changes in microvascularity has been suggested [12,
13]. Many mediators and growth factors which are directly
related to airway inﬂammation in asthma, such as histamine,
the major preformed mast cell mediator, prostaglandins,
leukotrienes, and cytokines, can simultaneously induce
vascular responses, such as angiogenesis vasodilation and
microvascular leakage [14–16]. However, the interpretation
of the speciﬁc role of many of these factors is often indirect
since it is based on studies of animal models, in vitro studies,
or studies performed on sites other than asthmatic airways.
If only in vivo and asthmatic airway studies are consid-
ered, vascular endothelial growth factor (VEGF) seems to
be particularly involved in the vascular changes in asthma.
VEGF is a potent multifunctional cytokine with several
important eﬀects such as acting on angiogenic sprouting
as well as on vascular leakage and permeability [17]. In
an in vivo study by Hoshino and coworkers [18], the
levels of three angiogenic factors, VEGF, basic ﬁbroblast
growth factor (bFGF), and angiogenin were signiﬁcantly
increased in the airways of asthmatic subjects compared
to controls. Moreover, the authors found a signiﬁcant
correlation between microvascularity and the amount of
angiogenic factors. Another interesting result of this study
was that in the submucosa the cells positive to angiogenic
factors were CD34+, eosinophils, and macrophages [18].
The results of the Hoshino study were subsequently
conﬁrmedandexpandedoninourlab.Inpatientswithmild-
to-moderate asthma, we found that in biopsy specimens of
bronchial mucosa the expression of VEGF was upregulated
as compared to controls [19]. We also found that VEGF was
related to the number of vessels and to the thickness of the
basement membrane [19]. Previous in vitro studies [20, 21]
have shown that VEGF expression can be associated with
ﬁbrosis and the remodelling processes. Interestingly, we have
shown a relationship between VEGF and the number of mast
cells [19]. Thanks to colocalization analysis we were able
to demonstrate that in asthmatics, mast cells were a main
cellular source of VEGF. Our ﬁndings further support the
view that mast cells can release VEGF and contribute to the
angiogenesis process in asthma.
Notably, according to the protease content, mast cells
are a heterogeneous group of cells and can be divided into
those that express tryptase but not chymase and those that
express tryptase and chymase. In asthmatic airways, we have
demonstrated that a substantial subset of mast cells (about
25%) express chymase [22]. We also have found that there is
a close relationship between VEGF expression and chymase
positive mast cells [22]. Colocalization analysis on sequential
sections of bronchial mucosa showed chymase positive mast
cells as a source of VEGF [22]. Thus, our results suggest that
chymase positive mast cells may play a role in the vascular
component of airway remodelling in asthma.
The remodelling process might be beneﬁcial in airway
disease and it has been suggested that airway wall-thickening
protects against airway narrowing and air trapping by
making the airway wall stiﬀer [23]. However, the detrimental
eﬀects seem to be more important than the protective
ones. Notably, remodelling may increase the irreversible
component of airway obstruction, accelerate the decline in
pulmonary function, and facilitate the persistence of airway
hyperresponsiveness, the loss of smooth muscle stretch
relaxation, the increase in contractile response, and the loss
of elastic recoil [24]. The clinical relevance of the various
airway structural changes, particularly of airway vascular
remodelling, remains to be determined.
There are very few results concerning the impact of
airway microvascularity on clinical features and pulmonary
function in asthma. Some studies [3, 25, 26] showed a
direct relationship between an increase in microvascularity,
expressed as the density of vessels, and the severity of
asthma. Thus, the airway wall of severe asthmatics was
more vascularized than that of mild-to-moderate patients.
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both having and not having steroid treatment, the density
of vessels was found to be weakly related to bronchial
hyperresponsiveness to methacholine, showing that vessel
density was greater in those patients with the most marked
hyperresponsiveness. The same study also showed a sig-
niﬁcant positive correlation between percentage change in
forced expiratory volume in the 1st second (FEV1)a f t e r
bronchodilator and number of vessels/mm2 for the asthma
patients overall. Taken together the ﬁndings of the Orsida et
al. study [27] suggest that the increased microvascularity in
airways may have pathophysiological relevance in asthma.
Hashimoto et al. [3] assessed the relative impact of the
increased microvascularity of medium and small airways on
airﬂowlimitationinnineasthmaticpatients,whounderwent
lobectomy or pneumonectomy for a solitary peripheral
carcinoma. In this study, the FEV1, expressed as a percentage
ofpredictedvalue,correlatedwiththevascularityintheinner
area of the medium airways, but not in the small airways.
Thus,thoughcorrelationdoesnotimplycausality,theresults
ofthestudybyHashimotoetal.[3]suggestthattheenhanced
vascularity in the inner area of the medium airways, but not
in the small airways, might contribute to airﬂow limitation
in patients with asthma.
3. VascularRemodellinginCOPD
Epithelial damage and mucus gland hyperplasia are the
structural changes which mostly characterize airway wall-
remodelling in COPD, even if subepithelial collagen deposi-
tion, increased smooth muscle, and vascular changes can be
also observed [24] (Figure 1). When the structural changes
of the airway wall in asthma and COPD are compared, the
vascular component of airway remodelling seems to be less
represented in COPD [24]. Thus, in contrast to asthma,
angiogenesisintheairwaywalldoesnotappeartobeatypical
feature of COPD.
Up to now, invivostudiesconcerningvascularchangesof
the bronchial wall in COPD airways have provided diﬀerent
results. Unlike the study by Kuwano et al. [28], which did
not ﬁnd any signiﬁcant diﬀerence in vascular area between
patients with mild COPD and controls, more recent studies
by Hashimoto et al. [3], Calabrese et al. [29], and Zanini et
al. [4] have shown that the vascular area of the airway wall
was increased in COPD patients, as compared to controls.
Notably, Hashimoto et al. [3] showed that, compared to
controls, the vasculararea was increased in the small airways,
but not in the medium airways. Yet, in the same study no
correlation was found between the degree of vascularity and
airﬂow limitation in patients with COPD.
In the study by Calabrese et al. [29], the authors exam-
ined mucosal microvascularity in large airways of current
smokers with COPD and they found a signiﬁcant diﬀerence
in vascular area in comparison to controls. Similarly to
the Hashimoto et al. study [3], in this study [29]n o
correlation between microvascularity data and clinical and
functional data were observed. No diﬀerence was also found
between symptomatic smokers with normal function and
symptomatic smokers with moderate COPD. Finally, the
authors showed an increase in bronchial vascularity, which
was associated with higher cellular expression of VEGF and
vascular expression of αvβ3 integrin [29]. αvβ3 integrin
is an adhesion molecule that is upregulated in new vessel
proliferation in response to angiogenic stimuli, while it is
expressed at low levels or absent on resting endothelium
[30]. Interestingly, it has been recently observed that VEGF
and αvβ3 integrin can synergistically exert angiogenic eﬀects
[31].
Zanini et al. [4] assessed bronchial vascular remodelling
in the central airways of COPD patients and showed that
the bronchial vascular area and vessel size were increased,
as compared to those of control subjects. Moreover, they
found a higher bronchial expression of VEGF, bFGF, and
transforming growth factor-beta (TGF-β) in COPD patients,
as compared to controls, and provided the evidence that
the vascular component of airway remodelling was positively
related to the bronchial expression of VEGF and TGF-β.
To further conﬁrm the role of vascular changes in the
airway walls of COPD patients, Soltani et al. [32]h a v e
recently shown that airway remodelling in smokers and
in patients with mild-to-moderate COPD was associated
with fragmentation of the reticular basement membrane and
altereddistributionofvesselsintheairwaywall.Thereticular
basement membrane showed fragmentation and splitting in
both the current smokers group and the ex-smoker with
COPD group compared with healthy nonsmokers. Reticular
basement membrane fragmentation was also equally present
in ex-smokers with COPD. The number of vessels staining
for VEGF in the reticular basement membrane was higher
in both the current smoker and ex-smoker COPD groups,
as compared to healthy nonsmokers. These morphological
features may have potential physiological consequences in
COPD. In that study [32], the authors found that in
current smokers with COPD, VEGF vessel staining positively
correlatedwithFEV1,expressedaspercentofpredictedvalue.
Similarly to what was found in asthmatic airways, VEGF
also seems to be a protein crucially involved in the vascular
remodelling of COPD. In the study by Kranenburg and
coworkers [33], COPD airways were associated with an
increased expression of VEGF in several cell populations,
suchasinthebronchial,bronchiolar,andalveolarepithelium
and in bronchiolar macrophages, as well as airway smooth
muscle and vascular smooth muscle cells in both the
bronchiolar and alveolar regions. These authors also found
a signiﬁcant inverse correlation between VEGF and FEV1 in
bronchial mucosal microvessels and airway smooth muscle
cells, bronchiolar epithelium, and medial vascular smooth
muscle cells of larger pulmonary arteries associated with
bronchiolar airways. Although association does not establish
causality, taken together, these ﬁndings strongly suggest a
role for VEGF in airway and vascular remodelling, and
thereby in the development of airway obstruction in COPD.
Vascular structural changes in airway mucosa of COPD
patients do not seem to imply any quantitative change in
Qaw, even if qualitative changes may occur. Contrary to what
has been shown in asthmatic patients in whom Qaw levels
were increased [10], patients with COPD may show normal
Qaw levels.Qaw wasmeasuredinage-matchedhealthycurrent4 International Journal of Endocrinology
smokers, healthy ex-smokers, ex-smokers with COPD, and
healthylifetimenonsmokersanditdidnotsigniﬁcantlydiﬀer
among groups [34]. The authors also found that Salbutamol
inhalationincreasedQaw signiﬁcantlyinlifetimenonsmokers
and healthy ex-smokers, but not in healthy current smokers
and ex-smokers with COPD [34]. Similarly, Paredi et al.
[35] found that Qaw was similar in patients with COPD, as
compared to healthy subjects and that, after the inhalation
of 200 mcg of Salbutamol, it was signiﬁcantly more elevated
in controls in comparison to COPD patients. Taken together
the ﬁndings of these studies [34, 35] indicate that cigarette
smoking as well as COPD are associated with a blunted
vasodilator response to inhaled Salbutamol in the airway, as
an expression of endothelial dysfunction.
4.InhaledSteroidsandVascularRemodelling
inAsthma and inCOPD
Steroids can positively aﬀect all three main aspects of
the vascular component of airway remodelling in asthma:
vasodilatation, increased vascular permeability, and angio-
genesis [36]. There is evidence that inhaled ﬂuticasone
propionate can act on the blood ﬂow in the bronchial
mucosa by causing vasoconstriction [37]. In addition, the
vasoconstrictor response was greater in subjects with higher
baseline airway mucosal blood ﬂow irrespective of whether
they were asthmatic or normal [37]. These ﬁndings suggest
that inhaled steroids have potentially beneﬁcial eﬀects in
asthma, that are not related to their anti-inﬂammatory
action.
Steroid-induced vasoconstriction is complex and diﬀer-
ent cellular mechanisms may occur [38]. These mechanisms
a r et o or a p i dt oi n v o l v eg e n ee x p r e s s i o na n dh a v et e r m e d
nongenomic actions [38]. Rapid nongenomic mechanisms
of corticosteroid actions are initiated by speciﬁc interactions
with membrane-bound or cytosolic glucocorticoid receptors
or nonspeciﬁc interactions with the cell membrane [38].
It is of note that steroids can act via noradrenergic neu-
rotransmission by potentiating the physiological eﬀect of
noradrenaline. It has been shown that corticosteroids can
increase the sensitivity of vascular smooth muscle to the
vasoconstrictoreﬀectsofnoradrenaline,aneﬀectreversedby
infusions of arachidonic acid and prostacyclin [39]. Steroids
can also exert a vasoconstrictive action by nonadrenergic
neurotransmission mechanisms and/or by acting on nitric
o x i d el e v e l s[ 40, 41].
Steroids can act not only on airway blood ﬂow, but also
on endothelial dysfunction and airway blood vessel density
of asthmatic airways. In steroid-na¨ ıve patients with asthma,
who had a blunted vasodilator response to Salbutamol in the
airways, inhaled steroids administered for several weeks have
been found to restore normal β2-adrenergic responsiveness
[42]. It has been also shown that high doses of inhaled
beclomethasone dipropionate given for six months were
able to reduce airway wall vascularity, evaluated as both
vessel number and percent vascularity, in mild-to-moderate
asthmatic patients [43]. Similarly, high doses of ﬂuticasone
propionate were able to decrease the number of vessels and
percent of vascular area as well as VEGF expression in the
bronchial mucosa of asthmatic patients [1]. Moreover, Asai
et al. [44] found that VEGF levels in induced sputum of
asthmatic patients were reduced after long-term treatment
with beclomethasone dipropionate. Kanazawa et al. [45] also
showed that ﬂuticasone treatment was able to reduce VEGF
and angiopoietin-1 levels and to improve airway microvas-
cular permeability. Taken together these ﬁndings support the
view that steroids can downregulate vascular remodelling
in asthmatic airways by acting on proangiogenic factors.
In addition, steroid eﬀects on endothelial dysfunction and
airway blood vessel density were likely to reﬂect a genomic
action as they were observed several hours after the last
steroid dose.
Studies on combination therapy with long-acting β2-
agonists and inhaled steroids have provided some interesting
results on a possible synergistic action on components of
vascularremodellinginasthma.Inasthmaticpatientstreated
with low-dose inhaled steroids, there was a positive eﬀect on
the vascular component of airway remodelling after a-three-
month treatment with inhaled salmeterol, with a signiﬁcant
decrease in the number of vessels [46]. A synergistic action
was not observed between LTRAs and steroids. When
montelukast was combined with ﬂuticasone propionate in
asthmatic patients, its eﬀect in reducing airway mucosal
blood ﬂow was not greater than when it was administered
alone [47].
Current treatment for COPD patients is predominantly
based on corticosteroids and bronchodilators, such as β2-
agonists and anticholinergics [48]. The eﬀect of these drugs
on bronchial microvascularity has been scarcely investigated
in COPD airways. Recently, we have demonstrated that
in COPD patients airway vascular remodelling may be
aﬀected by inhaled steroids [4]. As compared to untreated
COPD patients, COPD patients treated with high doses
of beclomethasone showed lower values of vascular area
and VEGF and bFGF expression [4]. Interestingly, in ex-
smokers with COPD, who showed a blunted vasodilator
response to inhaled Salbutamol in the airways, combined
glucocorticoid/long-acting β2-adrenergic agonist treatment
restoredtheresponsivenesstotheβ2-adrenergicagonist[34].
The role of endothelial dysfunction in the pathophysiology
of COPD and the clinical implications of its reversibility
induced by inhaled steroids are still subject of speculation
[11]. However, it is conceivable that inhaled steroids have
ab e n e ﬁ c i a le ﬀect even in extrapulmonary vascular dysfunc-
tionandthisfactcouldexplainthereductionintheincidence
of fatal and nonfatal cardiovascular events associated to
steroid treatment in COPD patients [11].
5. Conclusions
In conclusion, there is evidence that the airway wall is
more vascularized in asthmatic and COPD patients than
in healthy subjects, though this phenomenon is more
evident in asthma than in COPD. Notably, angiogenesis
and vascular leakage seem to be prevalent in asthma, while
vasodilation and vascular leakage seem to prevail in COPD.International Journal of Endocrinology 5
Although airway mucosal vessels can contribute to airway
ﬂow obstruction by angiogenetic processes, vasodilation,
and increased microvascular permeability, the clinical and
functional relevance of vascular remodelling remain to be
determined in chronic obstructive airway diseases.
Considering conventional antiasthma therapy, only cor-
ticosteroids can positively act on the three aspects of vascular
remodelling: angiogenesis, dilation, and permeability, and
there is evidence that steroids can downregulate vascular
remodelling in asthmatic airways by acting on proangio-
genic factors. It is likely that corticosteroids may aﬀect
airway microvascularity changes also in COPD. Interestingly,
inhaled corticosteroids may positively act on endothelial
dysfunction both in asthma and COPD. VEGF is the most
speciﬁc growth factor for vascular endothelium and it is
crucially involved in the pathophysiology of airway vascular
remodelling, both in asthma and COPD. The inhibition of
VEGF and its receptors may be potentially useful in the
treatment of vascular changes in the airway wall.
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